Humana Inc. (LON:0J6Z)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 32.46B +37.1% |
| Revenue (ttm) | 109.80B +18.3% |
| Net Income | 963.98M -18.8% |
| EPS | 7.98 -18.8% |
| Shares Out | n/a |
| PE Ratio | 33.67 |
| Forward PE | 27.67 |
| Dividend | 2.66 (0.97%) |
| Ex-Dividend Date | Jun 26, 2026 |
| Volume | 65 |
| Open | 368.80 |
| Previous Close | 374.35 |
| Day's Range | 363.22 - 375.54 |
| 52-Week Range | 162.00 - 436.26 |
| Beta | 0.72 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Humana
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and... [Read more]
Financial Performance
In 2025, Humana's revenue was $129.66 billion, an increase of 10.11% compared to the previous year's $117.76 billion. Earnings were $1.19 billion, a decrease of -1.57%.
Financial numbers in USD Financial StatementsNews
Humana price target raised to $370 from $350 at TD Cowen
TD Cowen analyst Ryan Langston raised the firm’s price target on Humana (HUM) to $370 from $350 and keeps a Hold rating on the shares. The firm said while a…
Humana price target raised to $407 from $344 at Barclays
Barclays raised the firm’s price target on Humana (HUM) to $407 from $344 and keeps an Equal Weight rating on the shares.
Piper upgrades Humana to Overweight on enterprise earnings growth
Piper Sandler upgraded Humana (HUM) to Overweight from Neutral with a price target of $463, up from $254. The stock in early trading is down 1% to $362.77. Instead of…
Humana upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler analyst Jessica Tassan upgraded Humana (HUM) to Overweight from Neutral with a price target of $463, up from $254.
Humana price target raised to $405 from $320 at UBS
UBS raised the firm’s price target on Humana (HUM) to $405 from $320 and keeps a Neutral rating on the shares.
Humana upgraded to Outperform from Market Perform at Leerink
Leerink analyst Whit Mayo upgraded Humana (HUM) to Outperform from Market Perform with a $513 price target Looking at probable earnings power scenarios for 2028, the firm contends that the…
Humana price target lowered to $436 from $441 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Humana (HUM) to $436 from $441 and keeps a Buy rating on the shares. The company reported a solid Q2 beat and…
Humana price target raised to $405 from $340 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised the firm’s price target on Humana (HUM) to $405 from $340 and keeps an Outperform rating on the shares following the company’s earnings report. Overall,…
Humana price target raised to $390 from $205 at Baird
Baird raised the firm’s price target on Humana (HUM) to $390 from $205 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results where…
Humana price target raised to $471 from $269 at Guggenheim
Guggenheim raised the firm’s price target on Humana (HUM) to $471 from $269 and keeps a Buy rating on the shares, rolling forward the firm’s same target multiple onto its…
Humana downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst John Ransom downgraded Humana (HUM) to Market Perform from Outperform without a price target The Star ratings announcements over the next two months create a “binary event,”…
Evercore upgrades Humana to Outperform on improved outlook
As previously reported, Evercore ISI upgraded Humana (HUM) to Outperform from In Line with a price target of $480, up from $430, post the company’s Q2 results. Through a combination…
Humana upgraded to Outperform from In Line at Evercore ISI
Evercore ISI upgraded Humana (HUM) to Outperform from In Line with a price target of $480, up from $430.
Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Humana tops quarterly estimates, maintains profit outlook as medical costs stay in line
Humana reported second-quarter results that topped estimates, as the health insurer's spending on medical services came in line with expectations. The company also maintained its 2026 adjusted profit...
Humana upgraded to Buy at BofA with bear scenario appearing ‘off the table’
As previously reported, BofA analyst Kevin Fischbeck upgraded Humana (HUM) to Buy from Neutral with a price target of $500, up from $410. Humana has indicated that its Medicare Advantage…
Humana upgraded to Buy from Neutral at BofA
BofA upgraded Humana (HUM) to Buy from Neutral with a price target of $500, up from $410.
Humana Earnings Call Transcript: Q2 2026
Performance is on track with expectations, supported by cost control, margin expansion, and operational improvements. Stars program progress and value-based care are driving quality and financial results, while strategic divestitures and capital initiatives enhance flexibility.
Humana Earnings release: Q2 2026
Humana released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Humana Quarterly report: Q2 2026
Humana has published its Q2 2026 quarterly earnings report on July 29, 2026.
Humana Profits Hit $694 Million As Medicare Costs Fall In Line
Humana reported second quarter net income of $694 million as costs of care for older adults in its Medicare Advantage plans fell in line with company expectations.
Humana Elects Paul Smith and Frederick Crawford to Board of Directors
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today announced that the Company's Board of Directors has elected Paul Smith and Frederick Crawford as new Board members, effective immediatel...
Humana Cuts Outlook Again on Lower Medicare Ratings
Humana cut its earnings outlook for the year, as the company continues to face earnings headwinds from lower Medicare Advantage Star Ratings for 2026.
Humana beats quarterly profit estimates as medical costs stay in line
Humana on Wednesday beat Wall Street estimates for second-quarter earnings as the health insurer's spend on medical services was in line with expectations, but it left its annual adjusted profit for...